MCID: ADM013
MIFTS: 63

Adamantinoma of Long Bones

Categories: Bone diseases, Cancer diseases, Rare diseases

Aliases & Classifications for Adamantinoma of Long Bones

MalaCards integrated aliases for Adamantinoma of Long Bones:

Name: Adamantinoma of Long Bones 58 60 45
Long Bone Adamantinoma 12 15
60

Characteristics:

Orphanet epidemiological data:

60

Inheritance: Not applicable; Prevalence: <1/1000000 (Europe),1-9/1000000 (Worldwide); Age of onset: Adolescent,Adult,Childhood; Age of death: normal life expectancy;

OMIM:

58
Inheritance:
autosomal dominant


HPO:

33
adamantinoma of long bones:
Inheritance autosomal dominant inheritance


Classifications:

Orphanet: 60  
Rare bone diseases


External Ids:

Disease Ontology 12 DOID:2775
OMIM 58 102660
MeSH 45 C562741
SNOMED-CT 69 56763007
MESH via Orphanet 46 D050398
ICD10 via Orphanet 35 C40.2
UMLS via Orphanet 75 C1367554
Orphanet 60 ORPHA55881
MedGen 43 C0334556
UMLS 74 C0334556

Summaries for Adamantinoma of Long Bones

CDC : 3 Acanthamoeba is a microscopic, free-living ameba, or amoeba* (single-celled living organism), that can cause rare**, but severe infections of the eye, skin, and central nervous system. The ameba is found worldwide in the environment in water and soil. The ameba can be spread to the eyes through contact lens use, cuts, or skin wounds or by being inhaled into the lungs. Most people will be exposed to Acanthamoeba during their lifetime, but very few will become sick from this exposure. The three diseases caused by Acanthamoeba are:

MalaCards based summary : Adamantinoma of Long Bones, also known as long bone adamantinoma, is related to osteofibrous dysplasia and lung cancer. An important gene associated with Adamantinoma of Long Bones is TP53 (Tumor Protein P53), and among its related pathways/superpathways are Signaling by GPCR and Innate Immune System. The drugs Prednisone and Hydrocortisone acetate have been mentioned in the context of this disorder. Affiliated tissues include bone, brain and breast, and related phenotypes are bone pain and pathologic fracture

Disease Ontology : 12 An adamantinoma that is located in the long bones and results in focal epithelial differentiation.

Wikipedia : 77 Adamantinoma (from the Greek word adamantinos, meaning "very hard") is a rare bone cancer, making up... more...

Description from OMIM: 102660

Related Diseases for Adamantinoma of Long Bones

Diseases related to Adamantinoma of Long Bones via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 183)
# Related Disease Score Top Affiliating Genes
1 osteofibrous dysplasia 11.6
2 lung cancer 11.5 ATM BRAF CDKN2A ERBB2 HRAS MET
3 breast cancer 11.5 ATM BRAF ERBB2 GNAS HRAS MET
4 colorectal cancer 11.4 BRAF CDKN2A ERBB2 GNAS HRAS MET
5 glioblastoma 11.3 BRAF CDKN2A ERBB2 HRAS MET MYC
6 adenocarcinoma 11.3 BRAF CDKN2A ERBB2 GNAS HRAS MYC
7 squamous cell carcinoma, head and neck 11.3 BRAF CDKN2A ERBB2 GNAS HRAS MET
8 large intestine cancer 11.3 BRAF CDKN2A ERBB2 GNAS HRAS MET
9 lung cancer susceptibility 3 11.3 BRAF CDKN2A ERBB2 GNAS HRAS MET
10 hepatocellular carcinoma 11.3 CDKN2A GNAS HRAS MET MIR200A MIR200B
11 gastric adenocarcinoma 11.2 BRAF CDKN2A ERBB2 GNAS HRAS MET
12 tibial adamantinoma 11.2
13 ovarian cancer 11.2 ATM BRAF ERBB2 MIR200A MIR200B MIR200C
14 pancreas adenocarcinoma 11.2 CDKN2A ERBB2 GNAS HRAS MET MYC
15 cervical cancer 11.2 CDKN2A ERBB2 GNAS HRAS MYC PIK3CA
16 endometrial cancer 11.2 BRAF CDKN2A ERBB2 HRAS MIR200C MYC
17 thyroid cancer 11.2 BRAF GNAS HRAS MET MYC NRAS
18 prostate cancer 11.2 ERBB2 HRAS MET MIR200B MYC PIK3CA
19 squamous cell carcinoma 11.2 BRAF CDKN2A ERBB2 HRAS PIK3CA PTEN
20 respiratory system cancer 11.2 CDKN2A ERBB2 HRAS MET MYC PIK3CA
21 renal cell carcinoma, papillary, 1 11.1 ATM BRAF ERBB2 HRAS MET NRAS
22 gastrointestinal system cancer 11.1 CDKN2A ERBB2 HRAS MET MYC PIK3CA
23 glioblastoma multiforme 11.1 CDKN2A ERBB2 MET MYC PIK3CA PTEN
24 endocrine gland cancer 11.1 CDKN2A ERBB2 GNAS HRAS MYC PTEN
25 cholangiocarcinoma 11.1 BRAF CDKN2A ERBB2 MET MIR200B PIK3CA
26 melanoma, cutaneous malignant 1 11.1 BRAF CDKN2A HRAS NRAS PIK3CA PTEN
27 brain cancer 11.1 BRAF HRAS MYC NRAS PIK3CA PTEN
28 melanoma 11.1 BRAF CDKN2A MIR200A MIR200B MIR200C NRAS
29 esophageal cancer 11.1 CDKN2A ERBB2 HRAS MYC PIK3CA PTEN
30 pancreatic cancer 11.1 CDKN2A ERBB2 HRAS MET PIK3CA SRC
31 gastric cancer 11.1 CDKN2A ERBB2 MET MIR200C MYC PIK3CA
32 bladder urothelial carcinoma 11.1 BRAF ERBB2 HRAS NRAS PIK3CA RB1
33 glioma 11.1 BRAF CDKN2A ERBB2 MET PIK3CA PTEN
34 bladder cancer 11.0 CDKN2A ERBB2 HRAS MYC RB1 SRC
35 ovarian serous cystadenocarcinoma 11.0 BRAF ERBB2 HRAS NRAS PIK3CA TP53
36 transitional cell carcinoma 11.0 BRAF CDKN2A ERBB2 HRAS PTEN TP53
37 small cell cancer of the lung 11.0 CDKN2A MYC PIK3CA PTEN RB1 TP53
38 testicular germ cell tumor 11.0 BRAF HRAS MIR200C PTEN STK11 TP53
39 differentiated thyroid carcinoma 11.0 BRAF HRAS MET NRAS RET TP53
40 sarcoma 11.0 BRAF HRAS PIK3CA RB1 SRC TP53
41 thyroid cancer, nonmedullary, 2 11.0 BRAF HRAS NRAS PIK3CA PTEN RET
42 adenoid cystic carcinoma 11.0 ATM ERBB2 HRAS PIK3CA PTEN TP53
43 myeloma, multiple 11.0 BRAF CDKN2A HRAS MYC NRAS TP53
44 lymphoma, non-hodgkin, familial 11.0 ATM BRAF MYC NRAS PIK3CA TP53
45 nasopharyngeal carcinoma 11.0 CDKN2A HRAS MYC NRAS PIK3CA TP53
46 medulloblastoma 11.0 ERBB2 MYC NRAS PIK3CA PTEN TP53
47 uterine anomalies 11.0 CDKN2A ERBB2 PIK3CA PTEN TP53
48 carcinosarcoma 11.0 ERBB2 HRAS PIK3CA PTEN TP53
49 nervous system cancer 11.0 CDKN2A MYC PTEN RB1 TP53
50 reproductive system disease 11.0 CDKN2A ERBB2 MYC PTEN TP53

Graphical network of the top 20 diseases related to Adamantinoma of Long Bones:



Diseases related to Adamantinoma of Long Bones

Symptoms & Phenotypes for Adamantinoma of Long Bones

Human phenotypes related to Adamantinoma of Long Bones:

60 33
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 bone pain 60 33 frequent (33%) Frequent (79-30%) HP:0002653
2 pathologic fracture 60 33 occasional (7.5%) Occasional (29-5%) HP:0002756
3 hypercalcemia 60 33 occasional (7.5%) Occasional (29-5%) HP:0003072
4 neoplasm 33 HP:0002664

Symptoms via clinical synopsis from OMIM:

58
Oncology:
adamantinoma of long bones

Clinical features from OMIM:

102660

GenomeRNAi Phenotypes related to Adamantinoma of Long Bones according to GeneCards Suite gene sharing:

27 (show all 17)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-2 10.88 HRAS PIK3CA BRAF
2 Decreased viability GR00221-A-1 10.88 CDKN2A HRAS MYC NRAS PIK3CA RET
3 Decreased viability GR00221-A-2 10.88 HRAS PIK3CA RET
4 Decreased viability GR00221-A-3 10.88 CDKN2A HRAS MYC NRAS ATM ERBB2
5 Decreased viability GR00221-A-4 10.88 CDKN2A PIK3CA RET ATM BRAF ERBB2
6 Decreased viability GR00231-A 10.88 RET
7 Decreased viability GR00301-A 10.88 RET BRAF
8 Decreased viability GR00381-A-1 10.88 BRAF
9 Decreased viability GR00402-S-2 10.88 CDKN2A HRAS MYC NRAS PIK3CA RET
10 Decreased focal adhesion (FA) area, decreased FA length, decreased FA mean intensity, increased number of small and round FAs, increased FA abundance GR00210-A 9.85 ATM ERBB2 HRAS NRAS PTEN STK11
11 Decreased cell migration GR00055-A-1 9.83 ATM BRAF HRAS MET PIK3CA
12 Decreased cella89culturea89derived Hepatitis C virus (HCVcc; Luca89Jc1) infection GR00234-A-2 9.58 ATM BRAF STK11
13 Increased cell viability after pRB stimulation GR00230-A-1 9.56 ERBB2 MET RET STK11
14 Reduced mammosphere formation GR00396-S 9.5 ATM BRAF GNAS HRAS MYC NRAS
15 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.47 ATM CDKN2A PTEN RB1 STK11 TP53
16 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.47 ATM BRAF CDKN2A MYC PTEN RB1
17 Increased simian virus 40 (SV40) infection GR00356-A-2 9.46 ATM BRAF MET SRC

MGI Mouse Phenotypes related to Adamantinoma of Long Bones:

47 (show all 27)
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.53 ATM BRAF CDKN2A ERBB2 GNAS HRAS
2 cardiovascular system MP:0005385 10.5 ATM BRAF CDKN2A ERBB2 GNAS HRAS
3 cellular MP:0005384 10.49 ATM BRAF CDKN2A ERBB2 GNAS MET
4 endocrine/exocrine gland MP:0005379 10.49 ATM BRAF CDKN2A ERBB2 GNAS HRAS
5 growth/size/body region MP:0005378 10.49 ATM BRAF CDKN2A ERBB2 GNAS HRAS
6 embryo MP:0005380 10.44 ATM BRAF CDKN2A ERBB2 MET MYC
7 homeostasis/metabolism MP:0005376 10.44 ATM BRAF CDKN2A ERBB2 GNAS HRAS
8 mortality/aging MP:0010768 10.41 ATM BRAF CDKN2A ERBB2 GNAS HRAS
9 immune system MP:0005387 10.4 ATM BRAF CDKN2A GNAS MET MYC
10 integument MP:0010771 10.39 ATM BRAF CDKN2A ERBB2 GNAS HRAS
11 digestive/alimentary MP:0005381 10.38 BRAF CDKN2A ERBB2 HRAS MET MYC
12 neoplasm MP:0002006 10.38 ATM BRAF CDKN2A ERBB2 GNAS HRAS
13 craniofacial MP:0005382 10.35 BRAF ERBB2 GNAS HRAS MET MYC
14 hematopoietic system MP:0005397 10.35 ATM BRAF CDKN2A GNAS MYC NRAS
15 nervous system MP:0003631 10.33 ATM BRAF CDKN2A ERBB2 GNAS HRAS
16 limbs/digits/tail MP:0005371 10.28 BRAF ERBB2 GNAS MET MYC NRAS
17 muscle MP:0005369 10.27 BRAF CDKN2A ERBB2 GNAS MET MYC
18 adipose tissue MP:0005375 10.23 ATM BRAF GNAS MYC PIK3CA PTEN
19 liver/biliary system MP:0005370 10.22 BRAF CDKN2A GNAS MET MYC NRAS
20 normal MP:0002873 10.18 BRAF ERBB2 GNAS HRAS MET MYC
21 no phenotypic analysis MP:0003012 10.17 CDKN2A GNAS HRAS MET MYC NRAS
22 reproductive system MP:0005389 10.03 ATM BRAF CDKN2A ERBB2 MYC PIK3CA
23 pigmentation MP:0001186 9.97 BRAF CDKN2A MYC NRAS PTEN RB1
24 renal/urinary system MP:0005367 9.97 BRAF GNAS HRAS MET PTEN RB1
25 respiratory system MP:0005388 9.93 BRAF CDKN2A ERBB2 GNAS HRAS MET
26 skeleton MP:0005390 9.73 BRAF CDKN2A ERBB2 GNAS HRAS MYC
27 vision/eye MP:0005391 9.32 BRAF CDKN2A MET NRAS PIK3CA PTEN

Drugs & Therapeutics for Adamantinoma of Long Bones

Drugs for Adamantinoma of Long Bones (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 86)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
2
Hydrocortisone acetate Approved, Vet_approved Phase 4 50-03-3
3
Hydrocortisone Approved, Vet_approved Phase 4 50-23-7 5754
4 Antineoplastic Agents, Hormonal Phase 4,Phase 1,Not Applicable
5 Hydrocortisone-17-butyrate Phase 4
6 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1
7 Anesthetics Phase 4
8 Hydrocortisone 17-butyrate 21-propionate Phase 4
9 glucocorticoids Phase 4,Phase 1
10 Anti-Inflammatory Agents Phase 4,Phase 1
11 Hydrocortisone hemisuccinate Phase 4
12 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1
13 Hormones Phase 4,Phase 3,Phase 2,Phase 1
14
Exenatide Approved, Investigational Phase 3,Phase 2 141758-74-9 15991534
15
Glucagon Approved Phase 3 16941-32-5
16
Diazoxide Approved Phase 3,Phase 2 364-98-7 3019
17 Hypoglycemic Agents Phase 3,Phase 2
18 Anti-Obesity Agents Phase 3,Phase 2
19 Incretins Phase 3,Phase 2
20 Glucagon-Like Peptide 1 Phase 3
21 Antihypertensive Agents Phase 3,Phase 2
22 Vasodilator Agents Phase 3,Phase 2
23
Trametinib Approved Phase 2 871700-17-3 11707110
24
Dabrafenib Approved, Investigational Phase 2 1195765-45-7 44462760 44516822
25
Vemurafenib Approved Phase 2 918504-65-1 23252090 42611257
26
Peginterferon alfa-2b Approved Phase 2 215647-85-1, 99210-65-8
27
Oxytocin Approved, Vet_approved Phase 2 50-56-6 53477758 439302
28
Metformin Approved Phase 2 657-24-9 14219 4091
29
Dopamine Approved Phase 2 62-31-7, 51-61-6 681
30
Memantine Approved, Investigational Phase 2 19982-08-2 4054
31
Irinotecan Approved, Investigational Phase 2 100286-90-6, 97682-44-5 60838
32
Methionine Approved, Nutraceutical Phase 2 63-68-3 6137
33 Protein Kinase Inhibitors Phase 2
34 Antiviral Agents Phase 2
35 Immunologic Factors Phase 2,Phase 1
36 Anti-Infective Agents Phase 2
37 Interferon-alpha Phase 2
38 interferons Phase 2
39 Radiopharmaceuticals Phase 2,Not Applicable
40 Fluorodeoxyglucose F18 Phase 2
41 Oxytocics Phase 2
42 insulin Phase 2
43 Insulin, Globin Zinc Phase 2
44 Angiogenesis Modulating Agents Phase 2,Phase 1
45 Angiogenesis Inhibitors Phase 2,Phase 1
46 CKD732 Phase 2
47 Neurotransmitter Agents Phase 2
48 Excitatory Amino Acids Phase 2
49 Antiparkinson Agents Phase 2
50 Excitatory Amino Acid Antagonists Phase 2

Interventional clinical trials:

(show all 43)
# Name Status NCT ID Phase Drugs
1 Effect of Perioperative Glucocorticoid Replacement on Prognosis of Surgical Patients With Sellar Lesions Unknown status NCT02190994 Phase 4 Hydrocortisone;Prednisone
2 SCRT Versus Conventional RT in Children and Young Adults With Low Grade and Benign Brain Tumors Unknown status NCT00517959 Phase 3
3 Efficacy and Safety of Exenatide in the Treatment of Hypothalamic Obesity After Craniopharyngioma Therapy Completed NCT02860923 Phase 3 Exenatide;Placebo
4 Effect of Diazoxide on the Obesity Secondary to Hypothalamic-pituitary Lesions Completed NCT00306683 Phase 3 DIAZOXIDE
5 Dabrafenib and Trametinib in Treating Patients With BRAF Mutated Ameloblastoma Recruiting NCT02367859 Phase 2 Dabrafenib;Trametinib
6 Vemurafenib and Cobimetinib in Treating Patients With BRAF V600E Mutation Positive Craniopharyngioma Recruiting NCT03224767 Phase 2 Vemurafenib;Cobimetinib
7 Management of Pediatric Craniopharyngioma by a Combination of Partial Surgical Resection, and Protontherapy (Craniopharyngioma) Active, not recruiting NCT02842723 Phase 2
8 A Phase II Trial of Intensity-Modulated Proton Therapy for Incompletely Resected Craniopharyngioma and Observation for Craniopharyngioma After Radical Resection Recruiting NCT02792582 Phase 2
9 Peginterferon Alfa-2b in Treating Younger Patients With Craniopharyngioma That is Recurrent or Cannot Be Removed By Surgery Completed NCT01964300 Phase 2
10 A Phase II Trial of Limited Surgery and Proton Therapy for Craniopharyngioma or Observation After Radical Resection Active, not recruiting NCT01419067 Phase 2 ^1^8F-fluorodeoxyglucose;^1^1C-methionine
11 Intranasal Oxytocin in Hypothalamic Obesity Recruiting NCT02849743 Phase 2 Syntocinon;Placebo (for Syntocinon)
12 Hypothalamic Obesity Following Craniopharyngioma Surgery: A Pilot Trial of Combined Metformin and Diazoxide Therapy Completed NCT00892073 Phase 2 Diazoxide;Metformin
13 An Efficacy, Safety, and Pharmacokinetics Study of Beloranib in Obese Subjects With Hypothalamic Injury Completed NCT02063295 Phase 2 ZGN-440 sterile diluent;ZGN-440 for injectable suspension
14 Weight Loss Study for Patients With Obesity Due to Craniopharyngioma or Other Brain Tumor Completed NCT01484873 Phase 2 Exenatide
15 Memantine for Prevention of Cognitive Late Effects in Pediatric Patients Receiving Cranial Radiation Therapy for Localized Brain Tumors Recruiting NCT03194906 Phase 2 Memantine
16 Methionine PET/CT Studies In Patients With Cancer Recruiting NCT00840047 Phase 2 Methionine
17 Irinotecan in Treating Children With Refractory Solid Tumors Completed NCT00004078 Phase 2 irinotecan hydrochloride
18 Neuromodulation for Hypothalamic Obesity Withdrawn NCT03708913 Phase 1
19 RO4929097, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Malignant Glioma Completed NCT01119599 Phase 1 Gamma-Secretase Inhibitor RO4929097;Temozolomide
20 Gamma-Secretase Inhibitor RO4929097 in Treating Young Patients With Relapsed or Refractory Solid Tumors, CNS Tumors, Lymphoma, or T-Cell Leukemia Terminated NCT01088763 Phase 1 gamma-secretase/Notch signalling pathway inhibitor RO4929097;dexamethasone
21 Vorinostat and Temozolomide in Treating Young Patients With Relapsed or Refractory Primary Brain Tumors or Spinal Cord Tumors Completed NCT01076530 Phase 1 vorinostat;temozolomide
22 Vorinostat and Bortezomib in Treating Young Patients With Refractory or Recurrent Solid Tumors, Including Central Nervous System Tumors and Lymphoma Completed NCT00994500 Phase 1 vorinostat;bortezomib
23 ABT-888 and Temozolomide in Treating Young Patients With Recurrent or Refractory CNS Tumors Completed NCT00946335 Phase 1 veliparib;temozolomide
24 Stereotactic Radiosurgery in Treating Patients With Brain Tumors Completed NCT00019578 Phase 1
25 Ispinesib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Lymphoma Completed NCT00363272 Phase 1 ispinesib
26 Positron Emission Tomography Using Fluorine F 18 EF5 to Find Oxygen in Tumor Cells of Patients Who Are Undergoing Surgery or Biopsy for Newly Diagnosed Brain Tumors Terminated NCT00110032 Phase 1 EF5
27 Lenalidomide in Treating Young Patients With Recurrent, Progressive, or Refractory CNS Tumors Completed NCT00100880 Phase 1 lenalidomide
28 Cilengitide in Treating Children With Refractory Primary Brain Tumors Completed NCT00063973 Phase 1 cilengitide
29 FR901228 in Treating Children With Refractory or Recurrent Solid Tumors or Leukemia Completed NCT00053963 Phase 1 romidepsin
30 Temozolomide and O6-Benzylguanine in Treating Children With Recurrent Brain Tumors Completed NCT00052780 Phase 1 O6-benzylguanine;temozolomide
31 Tumor Classification and Its Application in Surgical Treatment of Craniopharyngioma Unknown status NCT00949156
32 Prospective Pilot Study Identifying Clinically Relevant Biological Targets for Medical Therapy Recruiting NCT03610906
33 Examination of Sleep and Family Functioning in Pediatric Craniopharyngioma Patients Completed NCT03330080
34 Social Participation After Childhood Craniopharyngioma Completed NCT03139526
35 Prospective Study of Children and Adolescents With Craniopharyngioma Recruiting NCT01272622 Not Applicable
36 1.5T Intraoperative MR Imaging in Craniopharyngiomas Completed NCT01206543 Not Applicable
37 Weight Gain in Surgically Treated Adult-onset Craniopharyngioma Completed NCT01968603
38 Sleep Wake and Melatonin Pattern in Craniopharyngioma Completed NCT01881854
39 Observation of Young Patients Who Are Undergoing Surgery for Craniopharyngioma Completed NCT00258453 Not Applicable
40 Efficacy of 68Ga-DOTATOC Positron Emission Tomography (PET) CT in Children and Young Adults With Brain Tumors Withdrawn NCT02194452 Not Applicable
41 Molecular-Guided Therapy for Childhood Cancer Active, not recruiting NCT02162732 Not Applicable
42 Collecting and Storing Blood and Brain Tumor Tissue Samples From Children With Brain Tumors Completed NCT00919750
43 Collecting and Storing Tissue From Young Patients With Cancer Completed NCT00898755

Search NIH Clinical Center for Adamantinoma of Long Bones

Cochrane evidence based reviews: adamantinoma of long bones

Genetic Tests for Adamantinoma of Long Bones

Anatomical Context for Adamantinoma of Long Bones

MalaCards organs/tissues related to Adamantinoma of Long Bones:

42
Bone, Brain, Breast, Lung, Skin, Eye, Thyroid

The Foundational Model of Anatomy Ontology organs/tissues related to Adamantinoma of Long Bones:

20
The Long Bones

Publications for Adamantinoma of Long Bones

Articles related to Adamantinoma of Long Bones:

(show all 24)
# Title Authors Year
1
American College of Medical Genetics and Genomics technical standards and guidelines: microarray analysis for chromosome abnormalities in neoplastic disorders. ( 23619274 )
2013
2
Mesenchymal-epithelial differentiation of adamantinoma of long bones: an immunohistochemical and ultrastructural study. ( 22292734 )
2012
3
Analysis of stromal cells in osteofibrous dysplasia and adamantinoma of long bones. ( 21983933 )
2012
4
Opportunities and challenges associated with clinical diagnostic genome sequencing: a report of the Association for Molecular Pathology. ( 22918138 )
2012
5
Podoplanin expression in adamantinoma of long bones and osteofibrous dysplasia. ( 21499851 )
2011
6
Adamantinoma of long bones: a long-term follow-up study of 11 cases. ( 19048403 )
2009
7
MRI of adamantinoma of long bones in correlation with histopathology. ( 15547221 )
2004
8
Current trends in the management of adamantinoma of long bones. An international study. ( 10954102 )
2000
9
Expression of growth factors and their receptors in adamantinoma of long bones and the implication for its histogenesis. ( 9582523 )
1998
10
Cytogenetic analysis of adamantinoma of long bones: further indications for a common histogenesis with osteofibrous dysplasia. ( 9242211 )
1997
11
Distribution of extracellular matrix components in adamantinoma of long bones suggests fibrous-to-epithelial transformation. ( 9023400 )
1997
12
Adamantinoma of long bones. A histopathological and immunohistochemical study of 23 cases. ( 7567680 )
1995
13
DNA aberrations in the epithelial cell component of adamantinoma of long bones. ( 7495301 )
1995
14
Test and teach. Number seventy-nine. Diagnosis: Adamantinoma of long bones. ( 7892039 )
1994
15
A clinicopathological and immunohistochemical study of osteofibrous dysplasia, differentiated adamantinoma, and adamantinoma of long bones. ( 1281557 )
1992
16
Adamantinoma of long bones. A clinicopathologic study of 85 cases. ( 2743266 )
1989
17
Morphologic diversity of long bone adamantinoma. The concept of differentiated (regressing) adamantinoma and its relationship to osteofibrous dysplasia. ( 2804923 )
1989
18
Unusual localization of adamantinoma of long bones. Report of a case of isolated fibular involvement. ( 3944167 )
1986
19
Adamantinoma of long bones. ( 6493828 )
1984
20
Adamantinoma of long bones: clinical, pathological and ultrastructural features. ( 7201477 )
1982
21
An unusual case of adamantinoma of long bones. ( 7161313 )
1982
22
Ultrastructure of adamantinoma of long bones. ( 6270877 )
1981
23
Adamantinoma of long bones. A clinicopathological study of fourteen cases with vascular origin suggested. ( 1112840 )
1975
24
SO-CALLED ADAMANTINOMA OF LONG BONES. ( 14104305 )
1964

Variations for Adamantinoma of Long Bones

ClinVar genetic disease variations for Adamantinoma of Long Bones:

6 (show top 50) (show all 237)
# Gene Variation Type Significance SNP ID Assembly Location
1 ATM NM_000051.3(ATM): c.2441del (p.Asp814Alafs) deletion Pathogenic GRCh38 Chromosome 11, 108259050: 108259050
2 ATM NM_000051.3(ATM): c.2441del (p.Asp814Alafs) deletion Pathogenic GRCh37 Chromosome 11, 108129777: 108129777
3 ATM NM_000051.3(ATM): c.5696dup (p.Cys1899Trpfs) duplication Pathogenic GRCh37 Chromosome 11, 108178645: 108178645
4 ATM NM_000051.3(ATM): c.5696dup (p.Cys1899Trpfs) duplication Pathogenic GRCh38 Chromosome 11, 108307918: 108307918
5 NRAS NM_002524.4(NRAS): c.38G> T (p.Gly13Val) single nucleotide variant Pathogenic/Likely pathogenic rs121434596 GRCh38 Chromosome 1, 114716123: 114716123
6 NRAS NM_002524.4(NRAS): c.38G> T (p.Gly13Val) single nucleotide variant Pathogenic/Likely pathogenic rs121434596 GRCh37 Chromosome 1, 115258744: 115258744
7 CDKN2A NM_000077.4(CDKN2A): c.322G> T (p.Asp108Tyr) single nucleotide variant Likely pathogenic rs121913381 GRCh37 Chromosome 9, 21971036: 21971036
8 CDKN2A NM_000077.4(CDKN2A): c.322G> T (p.Asp108Tyr) single nucleotide variant Likely pathogenic rs121913381 GRCh38 Chromosome 9, 21971037: 21971037
9 BRAF NM_004333.5(BRAF): c.1785T> G (p.Phe595Leu) single nucleotide variant Pathogenic rs121913341 GRCh38 Chromosome 7, 140753350: 140753350
10 BRAF NM_004333.5(BRAF): c.1785T> G (p.Phe595Leu) single nucleotide variant Pathogenic rs121913341 GRCh37 Chromosome 7, 140453150: 140453150
11 HRAS NM_176795.4(HRAS): c.182A> G (p.Gln61Arg) single nucleotide variant Likely pathogenic rs121913233 GRCh37 Chromosome 11, 533874: 533874
12 HRAS NM_176795.4(HRAS): c.182A> G (p.Gln61Arg) single nucleotide variant Likely pathogenic rs121913233 GRCh38 Chromosome 11, 533874: 533874
13 MET NM_000245.3(MET): c.2975C> T (p.Thr992Ile) single nucleotide variant Conflicting interpretations of pathogenicity rs56391007 GRCh38 Chromosome 7, 116771936: 116771936
14 MET NM_000245.3(MET): c.2975C> T (p.Thr992Ile) single nucleotide variant Conflicting interpretations of pathogenicity rs56391007 GRCh37 Chromosome 7, 116411990: 116411990
15 MET NM_000245.3(MET): c.2908C> T (p.Arg970Cys) single nucleotide variant Conflicting interpretations of pathogenicity rs34589476 GRCh38 Chromosome 7, 116771869: 116771869
16 MET NM_000245.3(MET): c.2908C> T (p.Arg970Cys) single nucleotide variant Conflicting interpretations of pathogenicity rs34589476 GRCh37 Chromosome 7, 116411923: 116411923
17 BRAF NM_004333.4(BRAF): c.1796C> T (p.Thr599Ile) single nucleotide variant Pathogenic rs121913375 GRCh38 Chromosome 7, 140753339: 140753339
18 BRAF NM_004333.4(BRAF): c.1796C> T (p.Thr599Ile) single nucleotide variant Pathogenic rs121913375 GRCh37 Chromosome 7, 140453139: 140453139
19 BRAF NM_004333.5(BRAF): c.1391G> T (p.Gly464Val) single nucleotide variant Pathogenic/Likely pathogenic rs121913348 GRCh38 Chromosome 7, 140781617: 140781617
20 BRAF NM_004333.5(BRAF): c.1391G> T (p.Gly464Val) single nucleotide variant Pathogenic/Likely pathogenic rs121913348 GRCh37 Chromosome 7, 140481417: 140481417
21 GNAS NM_000516.5(GNAS): c.602G> A (p.Arg201His) single nucleotide variant Pathogenic/Likely pathogenic rs121913495 GRCh38 Chromosome 20, 58909366: 58909366
22 GNAS NM_000516.5(GNAS): c.602G> A (p.Arg201His) single nucleotide variant Pathogenic/Likely pathogenic rs121913495 GRCh37 Chromosome 20, 57484421: 57484421
23 GNAS NM_000516.5(GNAS): c.601C> T (p.Arg201Cys) single nucleotide variant Pathogenic/Likely pathogenic rs11554273 GRCh38 Chromosome 20, 58909365: 58909365
24 GNAS NM_000516.5(GNAS): c.601C> T (p.Arg201Cys) single nucleotide variant Pathogenic/Likely pathogenic rs11554273 GRCh37 Chromosome 20, 57484420: 57484420
25 PIK3CA NM_006218.4(PIK3CA): c.3140A> G (p.His1047Arg) single nucleotide variant Pathogenic rs121913279 GRCh38 Chromosome 3, 179234297: 179234297
26 PIK3CA NM_006218.4(PIK3CA): c.3140A> G (p.His1047Arg) single nucleotide variant Pathogenic rs121913279 GRCh37 Chromosome 3, 178952085: 178952085
27 RB1 NM_000321.2(RB1): c.1666C> T (p.Arg556Ter) single nucleotide variant Pathogenic rs121913304 GRCh38 Chromosome 13, 48381414: 48381414
28 RB1 NM_000321.2(RB1): c.1666C> T (p.Arg556Ter) single nucleotide variant Pathogenic rs121913304 GRCh37 Chromosome 13, 48955550: 48955550
29 RB1 NM_000321.2(RB1): c.2242G> T (p.Glu748Ter) single nucleotide variant Pathogenic/Likely pathogenic rs121913297 GRCh38 Chromosome 13, 48465028: 48465028
30 RB1 NM_000321.2(RB1): c.2242G> T (p.Glu748Ter) single nucleotide variant Pathogenic/Likely pathogenic rs121913297 GRCh37 Chromosome 13, 49039164: 49039164
31 HRAS NM_005343.4(HRAS): c.37G> T (p.Gly13Cys) single nucleotide variant Pathogenic rs104894228 GRCh38 Chromosome 11, 534286: 534286
32 HRAS NM_005343.4(HRAS): c.37G> T (p.Gly13Cys) single nucleotide variant Pathogenic rs104894228 GRCh37 Chromosome 11, 534286: 534286
33 TP53 NM_000546.5(TP53): c.743G> A (p.Arg248Gln) single nucleotide variant Pathogenic/Likely pathogenic rs11540652 GRCh38 Chromosome 17, 7674220: 7674220
34 TP53 NM_000546.5(TP53): c.743G> A (p.Arg248Gln) single nucleotide variant Pathogenic/Likely pathogenic rs11540652 GRCh37 Chromosome 17, 7577538: 7577538
35 TP53 NM_000546.5(TP53): c.742C> T (p.Arg248Trp) single nucleotide variant Pathogenic rs121912651 GRCh38 Chromosome 17, 7674221: 7674221
36 TP53 NM_000546.5(TP53): c.742C> T (p.Arg248Trp) single nucleotide variant Pathogenic rs121912651 GRCh37 Chromosome 17, 7577539: 7577539
37 PTEN NM_000314.4(PTEN): c.389G> A (p.Arg130Gln) single nucleotide variant Pathogenic rs121909229 GRCh38 Chromosome 10, 87933148: 87933148
38 PTEN NM_000314.4(PTEN): c.389G> A (p.Arg130Gln) single nucleotide variant Pathogenic rs121909229 GRCh37 Chromosome 10, 89692905: 89692905
39 STK11 NM_000455.4(STK11): c.508C> T (p.Gln170Ter) single nucleotide variant Pathogenic/Likely pathogenic rs121913323 GRCh38 Chromosome 19, 1220416: 1220416
40 STK11 NM_000455.4(STK11): c.508C> T (p.Gln170Ter) single nucleotide variant Pathogenic/Likely pathogenic rs121913323 GRCh37 Chromosome 19, 1220415: 1220415
41 VHL NM_000551.3(VHL): c.241C> T (p.Pro81Ser) single nucleotide variant Conflicting interpretations of pathogenicity rs104893829 GRCh38 Chromosome 3, 10142088: 10142088
42 VHL NM_000551.3(VHL): c.241C> T (p.Pro81Ser) single nucleotide variant Conflicting interpretations of pathogenicity rs104893829 GRCh37 Chromosome 3, 10183772: 10183772
43 STK11 NM_000455.4(STK11): c.996G> A (p.Trp332Ter) single nucleotide variant Likely pathogenic rs121913325 GRCh38 Chromosome 19, 1223060: 1223060
44 STK11 NM_000455.4(STK11): c.996G> A (p.Trp332Ter) single nucleotide variant Likely pathogenic rs121913325 GRCh37 Chromosome 19, 1223059: 1223059
45 STK11 NM_000455.4(STK11): c.595G> T (p.Glu199Ter) single nucleotide variant Likely pathogenic rs121913317 GRCh38 Chromosome 19, 1220503: 1220503
46 STK11 NM_000455.4(STK11): c.595G> T (p.Glu199Ter) single nucleotide variant Likely pathogenic rs121913317 GRCh37 Chromosome 19, 1220502: 1220502
47 STK11 NM_000455.4(STK11): c.595G> A (p.Glu199Lys) single nucleotide variant Likely pathogenic rs121913317 GRCh38 Chromosome 19, 1220503: 1220503
48 STK11 NM_000455.4(STK11): c.595G> A (p.Glu199Lys) single nucleotide variant Likely pathogenic rs121913317 GRCh37 Chromosome 19, 1220502: 1220502
49 STK11 NM_000455.4(STK11): c.581A> T (p.Asp194Val) single nucleotide variant Likely pathogenic rs121913316 GRCh38 Chromosome 19, 1220489: 1220489
50 STK11 NM_000455.4(STK11): c.581A> T (p.Asp194Val) single nucleotide variant Likely pathogenic rs121913316 GRCh37 Chromosome 19, 1220488: 1220488

Copy number variations for Adamantinoma of Long Bones from CNVD:

7 (show top 50) (show all 8840)
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 13322 1 1 124300000 Deletion Cancer
2 13338 1 1 124300000 Loss Cancer
3 13402 1 1 2300000 Gain or loss SKI Cancer
4 13748 1 1 27800000 Loss Cancer
5 14855 1 110683467 110690826 Gain or loss RBM15 Cancer
6 14882 1 11089178 11245151 Gain or loss FRAP1 Cancer
7 15022 1 111886577 112057624 Gain or loss RAP1A Cancer
8 15053 1 112169367 112371631 Insert KCND3 Cancer
9 15118 1 112811562 112865428 Gain or loss WNT2B Cancer
10 15156 1 113045271 113051548 Gain or loss RHOC Cancer
11 15168 1 113054138 113059473 Gain or loss PPM1J Cancer
12 15235 7 99974769 99991926 Amplification HRBL Cancer
13 15240 1 113734997 114030068 Gain or loss MAGI3 Cancer
14 15281 1 114238969 114352508 Amplification or deletion TRIM33 Cancer
15 15306 1 114548311 114558715 Amplification or deletion NRAS Cancer
16 15330 1 114736921 114855304 Gain or loss TRIM33 Cancer
17 15338 1 114736922 114855304 Amplification O75428 Cancer
18 15357 1 114911708 114925788 Amplification Q8TEE9 Cancer
19 15359 7 100009569 100021712 Amplification LRCH4 Cancer
20 15374 7 100021891 100036676 Amplification FBXO24 Cancer
21 15392 1 115048600 115061038 Gain or loss NRAS Cancer
22 15400 7 100037817 100043737 Amplification PCOLCE Cancer
23 15404 7 100047660 100050936 Amplification MOSPD3 Cancer
24 15409 7 100055974 100078338 Amplification TFR2 Cancer
25 15416 7 100078663 100091986 Amplification ACTL6B Cancer
26 15444 1 115630059 115682380 Gain or loss NGFB Cancer
27 15529 1 11657123 11674265 Gain or loss MAD2L2 Cancer
28 15602 7 100109310 100114728 Amplification GNB2 Cancer
29 15670 1 117922092 117959602 Deletion Cancer
30 15674 1 11796339 11809890 Deletion Cancer
31 18930 1 147942694 147943203 Amplification Cancer
32 18947 1 148000000 149600000 Amplification TARS2 Cancer
33 18960 1 148000899 148065680 Deletion ARNT Cancer
34 18964 13 36575396 36577801 Amplification CSNK1A1L Cancer
35 18966 13 37034778 37070874 Amplification POSTN Cancer
36 18968 13 37108794 37341935 Amplification TRPC4 Cancer
37 18970 13 37822017 37835139 Amplification UFM1 Cancer
38 18973 1 148070845 148077963 Amplification Cancer
39 18976 1 148077734 148079389 Amplification Q96JQ7 Cancer
40 18978 13 38159172 38359267 Amplification FREM2 Cancer
41 18980 13 38438061 38462983 Amplification STOML3 Cancer
42 18988 13 38482001 38510252 Amplification C13orf23 Cancer
43 18990 1 148090805 148091311 Amplification NP_001017370.1 Cancer
44 18992 13 38815028 39075356 Amplification LHFP Cancer
45 18996 13 39127813 39263802 Amplification COG6 Cancer
46 18998 1 148125149 148125585 Amplification Q8NEU3 Cancer
47 19000 1 148125698 148126090 Amplification Q96L18 Cancer
48 19004 13 39946130 40138734 Amplification FOXO1 Cancer
49 19009 13 40201431 40243347 Amplification MRPS31 Cancer
50 19011 13 40261596 40282246 Amplification SLC25A15 Cancer

Expression for Adamantinoma of Long Bones

Search GEO for disease gene expression data for Adamantinoma of Long Bones.

Pathways for Adamantinoma of Long Bones

Pathways related to Adamantinoma of Long Bones according to GeneCards Suite gene sharing:

(show top 50) (show all 177)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.32 BRAF ERBB2 GNAS HRAS MET MYC
2
Show member pathways
14.16 BRAF ERBB2 HRAS MET MYC NRAS
3
Show member pathways
14.02 ATM BRAF CDKN2A ERBB2 GNAS HRAS
4
Show member pathways
13.98 ATM BRAF CDKN2A ERBB2 GNAS HRAS
5
Show member pathways
13.88 BRAF CDKN2A ERBB2 GNAS HRAS MET
6
Show member pathways
13.81 BRAF ERBB2 GNAS HRAS MET MYC
7
Show member pathways
13.7 BRAF ERBB2 GNAS HRAS MET MYC
8
Show member pathways
13.63 BRAF ERBB2 HRAS MET NRAS PIK3CA
9
Show member pathways
13.59 ERBB2 HRAS MET NRAS PIK3CA PTEN
10
Show member pathways
13.55 ERBB2 GNAS HRAS MET NRAS PTEN
11
Show member pathways
13.54 BRAF GNAS HRAS MYC NRAS PIK3CA
12
Show member pathways
13.52 BRAF ERBB2 HRAS MET MYC NRAS
13
Show member pathways
13.45 ERBB2 GNAS HRAS MET NRAS PTEN
14
Show member pathways
13.41 BRAF ERBB2 GNAS HRAS MET NRAS
15
Show member pathways
13.38 BRAF ERBB2 GNAS HRAS MYC NRAS
16
Show member pathways
13.24 BRAF GNAS HRAS MET NRAS PTEN
17
Show member pathways
13.17 BRAF GNAS HRAS MET NRAS SRC
18
Show member pathways
13.16 BRAF CDKN2A GNAS HRAS NRAS SRC
19
Show member pathways
13.15 ATM CDKN2A GNAS HRAS MYC NRAS
20
Show member pathways
13.12 ATM ERBB2 GNAS HRAS MET MYC
21
Show member pathways
13.11 HRAS NRAS PIK3CA PTEN RB1 SRC
22
Show member pathways
13.1 BRAF GNAS HRAS MET NRAS PIK3CA
23
Show member pathways
13.07 BRAF ERBB2 HRAS MET NRAS PIK3CA
24
Show member pathways
13.06 BRAF ERBB2 HRAS MET NRAS PIK3CA
25
Show member pathways
13.03 BRAF ERBB2 GNAS HRAS NRAS PIK3CA
26
Show member pathways
13.02 BRAF GNAS HRAS NRAS PIK3CA SRC
27
Show member pathways
12.99 ATM CDKN2A HRAS MYC NRAS PIK3CA
28
Show member pathways
12.98 BRAF CDKN2A ERBB2 HRAS MYC NRAS
29
Show member pathways
12.97 BRAF HRAS NRAS PIK3CA SRC STK11
30 12.95 BRAF ERBB2 HRAS MET MYC NRAS
31
Show member pathways
12.92 BRAF GNAS HRAS NRAS SRC
32
Show member pathways
12.91 BRAF ERBB2 HRAS MET NRAS PIK3CA
33
Show member pathways
12.9 BRAF HRAS MYC PIK3CA PTEN
34
Show member pathways
12.9 BRAF GNAS HRAS MET NRAS PIK3CA
35
Show member pathways
12.9 ERBB2 HRAS MET NRAS PIK3CA PTEN
36
Show member pathways
12.9 BRAF CDKN2A ERBB2 HRAS MET MYC
37
Show member pathways
12.87 BRAF GNAS HRAS NRAS SRC
38
Show member pathways
12.84 GNAS HRAS NRAS PIK3CA PTEN SRC
39
Show member pathways
12.81 BRAF HRAS NRAS RB1 TP53
40
Show member pathways
12.8 BRAF GNAS HRAS NRAS SRC
41 12.79 BRAF CDKN2A ERBB2 GNAS HRAS MET
42
Show member pathways
12.78 BRAF ERBB2 HRAS MET MYC NRAS
43
Show member pathways
12.78 ATM BRAF CDKN2A ERBB2 GNAS HRAS
44
Show member pathways
12.77 ERBB2 HRAS MYC NRAS PIK3CA SRC
45 12.76 BRAF HRAS NRAS PIK3CA SRC
46
Show member pathways
12.73 HRAS NRAS PIK3CA PTEN SRC
47
Show member pathways
12.73 BRAF ERBB2 HRAS MYC NRAS PIK3CA
48
Show member pathways
12.71 ATM CDKN2A MYC RB1 TP53
49
Show member pathways
12.69 BRAF ERBB2 HRAS MET NRAS PIK3CA
50
Show member pathways
12.67 ERBB2 HRAS MYC NRAS PIK3CA PTEN

GO Terms for Adamantinoma of Long Bones

Cellular components related to Adamantinoma of Long Bones according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytoplasm GO:0005737 9.4 ATM BRAF CDKN2A ERBB2 GNAS HRAS

Biological processes related to Adamantinoma of Long Bones according to GeneCards Suite gene sharing:

(show all 44)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of gene expression GO:0010629 9.99 HRAS MIR200B MYC RB1
2 positive regulation of apoptotic process GO:0043065 9.99 ATM CDKN2A MIR200B PTEN SRC TP53
3 cell proliferation GO:0008283 9.95 ERBB2 HRAS MET MYC PTEN SRC
4 protein autophosphorylation GO:0046777 9.94 ATM ERBB2 SRC STK11
5 peptidyl-tyrosine phosphorylation GO:0018108 9.92 BRAF ERBB2 MET RET SRC
6 T cell receptor signaling pathway GO:0050852 9.91 BRAF HRAS PIK3CA STK11
7 cellular response to hypoxia GO:0071456 9.9 MYC PTEN SRC TP53
8 positive regulation of protein kinase B signaling GO:0051897 9.89 ERBB2 MET PIK3CA RET SRC
9 transmembrane receptor protein tyrosine kinase signaling pathway GO:0007169 9.88 ERBB2 MET RET SRC
10 regulation of signal transduction by p53 class mediator GO:1901796 9.85 ATM STK11 TP53
11 cellular response to retinoic acid GO:0071300 9.85 ATM MYC RET
12 cellular response to drug GO:0035690 9.85 BRAF MYC TP53
13 stimulatory C-type lectin receptor signaling pathway GO:0002223 9.84 HRAS NRAS SRC
14 positive regulation of epithelial cell proliferation GO:0050679 9.84 ERBB2 HRAS MYC
15 positive regulation of MAP kinase activity GO:0043406 9.83 ERBB2 HRAS SRC
16 positive regulation of cell adhesion GO:0045785 9.82 ATM ERBB2 SRC
17 MAPK cascade GO:0000165 9.8 BRAF ERBB2 HRAS MET MYC NRAS
18 positive regulation of MAPK cascade GO:0043410 9.79 ERBB2 HRAS RET
19 Ras protein signal transduction GO:0007265 9.77 CDKN2A HRAS NRAS RB1 TP53
20 cellular response to gamma radiation GO:0071480 9.76 ATM HRAS TP53
21 tissue homeostasis GO:0001894 9.73 GNAS RB1 STK11
22 positive regulation of response to DNA damage stimulus GO:2001022 9.69 ATM MYC
23 anoikis GO:0043276 9.69 PIK3CA STK11
24 negative regulation of telomerase activity GO:0051974 9.68 SRC TP53
25 neuron maturation GO:0042551 9.68 RB1 RET
26 entry of bacterium into host cell GO:0035635 9.67 MET SRC
27 regulation of axon regeneration GO:0048679 9.65 BRAF PTEN
28 replicative senescence GO:0090399 9.65 ATM CDKN2A TP53
29 negative regulation of immature T cell proliferation in thymus GO:0033088 9.64 CDKN2A ERBB2
30 negative regulation of apoptotic process GO:0043066 9.63 BRAF MIR200B MYC PTEN SRC TP53
31 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.62 BRAF HRAS PTEN SRC
32 cell cycle arrest GO:0007050 9.5 ATM CDKN2A HRAS MYC RB1 STK11
33 positive regulation of gene expression GO:0010628 9.32 ATM BRAF CDKN2A ERBB2 HRAS MYC
34 phosphatidylinositol phosphorylation GO:0046854 9.29 PIK3CA
35 signal transduction GO:0007165 10.28 ATM BRAF ERBB2 GNAS HRAS MET
36 positive regulation of transcription by RNA polymerase II GO:0045944 10.2 ATM CDKN2A HRAS MET MYC RB1
37 cell cycle GO:0007049 10.11 ATM CDKN2A RB1 SRC STK11 TP53
38 positive regulation of transcription, DNA-templated GO:0045893 10.1 CDKN2A MYC RB1 RET SRC TP53
39 apoptotic process GO:0006915 10.09 ATM CDKN2A HRAS PTEN RB1 STK11
40 phosphorylation GO:0016310 10.06 ATM BRAF ERBB2 MET PIK3CA RET
41 negative regulation of cell proliferation GO:0008285 10.04 CDKN2A HRAS PTEN RB1 STK11 TP53
42 protein phosphorylation GO:0006468 10.03 ATM BRAF ERBB2 MET PIK3CA RET
43 response to drug GO:0042493 10.02 GNAS MYC PTEN RET SRC
44 cell differentiation GO:0030154 10.01 BRAF RB1 RET SRC STK11 TP53

Molecular functions related to Adamantinoma of Long Bones according to GeneCards Suite gene sharing:

(show all 11)
# Name GO ID Score Top Affiliating Genes
1 ATP binding GO:0005524 9.97 ATM BRAF ERBB2 MET PIK3CA RET
2 protein kinase activity GO:0004672 9.85 BRAF ERBB2 MET RET SRC STK11
3 mRNA binding involved in posttranscriptional gene silencing GO:1903231 9.76 MIR200A MIR200B MIR200C MIR429
4 protein phosphatase binding GO:0019903 9.67 ERBB2 MET TP53
5 transmembrane receptor protein tyrosine kinase activity GO:0004714 9.61 ERBB2 MET RET
6 disordered domain specific binding GO:0097718 9.58 CDKN2A RB1 TP53
7 kinase activity GO:0016301 9.56 ATM BRAF ERBB2 MET PIK3CA RET
8 protein tyrosine kinase activity GO:0004713 9.55 BRAF ERBB2 MET RET SRC
9 nucleotide binding GO:0000166 9.17 ATM BRAF ERBB2 HRAS MET NRAS
10 phosphatidylinositol-4,5-bisphosphate 3-kinase activity GO:0046934 8.96 PIK3CA
11 transferase activity GO:0016740 10.08 ATM BRAF ERBB2 MET PIK3CA RET

Sources for Adamantinoma of Long Bones

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....